company background image
ITRM

Iterum Therapeutics NasdaqCM:ITRM Stock Report

Last Price

US$1.19

Market Cap

US$14.5m

7D

-14.7%

1Y

-83.7%

Updated

10 Dec, 2022

Data

Company Financials +
ITRM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

ITRM Stock Overview

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.

Iterum Therapeutics plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Iterum Therapeutics
Historical stock prices
Current Share PriceUS$1.19
52 Week HighUS$7.48
52 Week LowUS$1.16
Beta1.32
1 Month Change-16.84%
3 Month Change-49.57%
1 Year Change-83.68%
3 Year Change-97.26%
5 Year Changen/a
Change since IPO-99.39%

Recent News & Updates

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Aug 19
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Aug 12

Recent updates

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Aug 19
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

May 06
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Jan 12
Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Sep 25
Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Jun 11
It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

May 20
Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

Feb 04
Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Feb 04
This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Shareholder Returns

ITRMUS PharmaceuticalsUS Market
7D-14.7%-0.3%-2.8%
1Y-83.7%14.1%-19.6%

Return vs Industry: ITRM underperformed the US Pharmaceuticals industry which returned 14.1% over the past year.

Return vs Market: ITRM underperformed the US Market which returned -19.6% over the past year.

Price Volatility

Is ITRM's price volatile compared to industry and market?
ITRM volatility
ITRM Average Weekly Movement9.6%
Pharmaceuticals Industry Average Movement11.0%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: ITRM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ITRM's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201513Corey Fishmanhttps://www.iterumtx.com

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Iterum Therapeutics plc Fundamentals Summary

How do Iterum Therapeutics's earnings and revenue compare to its market cap?
ITRM fundamental statistics
Market CapUS$14.50m
Earnings (TTM)-US$43.53m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ITRM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$43.53m
Earnings-US$43.53m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.56
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio92.8%

How did ITRM perform over the long term?

See historical performance and comparison